Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Fujii

Sports Medicine Carmichael, CA Medical Doctor

NPI 1235391798 CMS profile 283163

6403 Coyle Ave Ste 170, Carmichael, CA 95608

Open in the dashboard

General payments

$3,853

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Fujii of Carmichael, CA is reported in the CMS Open Payments database as having received $3,853 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $293 10
2024 General $218 7
2023 General $401 17
2022 General $491 15
2021 General $486 14
2020 General $133 4
2019 General $1,829 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Fujii
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Scott Fujii were reported at $293. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Scott Fujii Sports Medicine median Middle half National median
2019 $1,829 $1,176 $199–$4,249 $163
2020 $133 $708 $96–$2,890 $114
2021 $486 $1,213 $152–$3,994 $132
2022 $491 $1,230 $159–$3,998 $149
2023 $401 $584 $146–$2,836 $160
2024 $218 $628 $163–$3,168 $164
2025 $293 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,166 33 payments
  2. Dynasplint Systems Inc. $204 2 payments
  3. Orthofix Medical, Inc. $183 8 payments
  4. Smith+Nephew, Inc. $130 7 payments
  5. DePuy Synthes Sales Inc. $110 5 payments
  6. Bioventus LLC $103 5 payments
  7. Horizon Therapeutics plc $96 6 payments
  8. Fidia Pharma USA Inc. $86 3 payments
  9. Ethicon US, LLC $65 2 payments
  10. Zimmer Biomet Holdings, Inc. $59 2 payments
  11. Other $650 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,069 102 payments
  2. Education $712 1 payment
  3. Travel and Lodging $71 1 payment
Products named General payments · program years 2019–2025
  1. TRIATHLON $712 1 payment
  2. MAKO Knees, Hips $427 10 payments
  3. MAKO Knees, Hips $383 10 payments
  4. REUNION $240 2 payments
  5. Physio-Stim $219 9 payments
  6. Dynasplint $204 2 payments
  7. GRAVITY SYNCHFIX $132 1 payment
  8. HYDROSET $132 1 payment
  9. CHAMPION SHOULDER INSTRUMENTATION SET $94 3 payments
  10. HYMOVIS $86 3 payments
  11. Other $2,066 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

159

Median for Orthopedic Surgery: 203

Drug cost

$1,790

Median for Orthopedic Surgery: $1,433

Branded share of claims

91.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 110 $1,168
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 36 $517
Ibuprofen Generic 13 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$186,007

Of which drugs: $12,325

Medicare patients

430

Average age 74

Services billed

4,315

299 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Depression 26%
Ischemic heart disease 24%
Osteoporosis 20%
Chronic kidney disease 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 17 1,350 $6,935
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 21 83 $4,360
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 185 1,384 $1,025

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record